Bioanalysis and the oncology revolution

References

• 1. Martin-Liberal J, Hierro C, Ochoa De Olza M, Rodon J. Immuno-oncology: the third paradigm in early drug development. Target Oncol. 12(2), 125–138 (2017).
  MedlineGoogle Scholar
• 2. Graul AI, Pina P, Cruces E, Stringer M. The year's new drugs and biologics 2018: part I. Drugs Today (Barc.) 55(1), 35–87 (2019).
  Medline CASGoogle Scholar
• 3. Blanco MJ, Gardinier KM. New chemical modalities and strategic thinking in early drug discovery. ACS Med. Chem. Lett. 11(3), 228–231 (2020).
  Medline CASGoogle Scholar
• 4. Webster RM. Combination therapies in oncology. Nat. Rev. Drug Discov. 15(2), 81–82 (2016).
  Medline CASGoogle Scholar
• 5. Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med. 8(1), 115 (2016).
  MedlineGoogle Scholar
• 6. Fumet J-D, Isambert N, Hervieu A et al. Evaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME). Ann. Oncol. 29(x31), 85P (2018).
  Google Scholar
• 7. Masuda N, Ohtani S, Takano T et al. A randomized, 3-arm, neoadjuvant, Phase II study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1 + P), and T-DM1 + P in HER2-positive primary breast cancer. Breast Cancer Res. Treat. 180(1), 135–146 (2020).
  Medline CASGoogle Scholar
• 8. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small-cell lung cancer: A United States-based cost–effectiveness analysis. Cancer 125(20), 3526–3534 (2019).
  Medline CASGoogle Scholar
• 9. Mateos M-V, Cavo M, Bladé J et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in Alcyone. Blood 134(Suppl. 1), 859 (2019).
  Google Scholar
• 10. O'malley DM, Richardson DL, Vergote IB et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer. Ann. Oncol. 31, S626–S627 (2020).
  MedlineGoogle Scholar
• 11. Paller CJ, Huang EP, Luechtefeld T et al. Factors affecting combination trial success (FACTS): investigator survey results on Early-Phase Combination Trials. Front Med. (Lausanne) 6, 122 (2019).
  MedlineGoogle Scholar
• 12. Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications. Clin. Cancer Res. 26(21), 5557–5566 (2020).
  Medline CASGoogle Scholar
• 13. Sicklick JK, Kato S, Okamura R et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25(5), 744–750 (2019).
  Medline CASGoogle Scholar
• 14. Roy S, Vallepu S, Barrios C, Hunter K. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J. Clin. Med. Res. 10(12), 911–919 (2018).
  MedlineGoogle Scholar
• 15. Kantilal K, Kantilal K, Barnett N. It's time for comprehensive polypharmacy reviews for older people with cancer. Pharm. J. 304(7933), (2020).
  Google Scholar
• 16. Rao Gajula SN, Reddy GN, Reddy DS, Sonti R. Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. Bioanalysis 12(22), 1647–1664 (2020).
  Google Scholar
• 17. Mou S, Huang Y, Rosenbaum AI. ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates. Antibodies (Basel) 7(4), 41 (2018).
  Medline CASGoogle Scholar
• 18. Hernandez-Alba O, Ehkirch A, Beck A, Cianférani S. Analysis of ADCs by native mass spectrometry. In: Antibody-Drug Conjugates: Methods and Protocols. Tumey LN (Ed.). Springer, NY, USA (2020).
  Google Scholar
• 19. Liu J, Li J, Tran C et al. Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry. Bioanalysis 11(21), 1967–1980 (2019).
  CASGoogle Scholar
• 20. Spengler M, Adler M, Niemeyer CM. Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. Analyst 140(18), 6175–6194 (2015).
  Medline CASGoogle Scholar
• 21. De Zwart M, Lausecker B, Globig S et al. Co-medication and interference testing in bioanalysis: a European Bioanalysis Forum recommendation. Bioanalysis 8(19), 2065–2070 (2016).
  Google Scholar
• 22. US FDA. Bioanalytical Method Validation Guidance for Industry (2018). https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf
  Google Scholar
• 23. European Medicines Agency. Guideline on Bioanalytical Method Validation (2011). https://www.ema.europa.eu/en/bioanalytical-method-validation
  Google Scholar
• 24. US FDA. M10 Bioanalytical Method Validation (2019). https://www.fda.gov/media/128343/download
  Google Scholar
• 25. Lowes S, Boterman M, Doig M et al. Recommendations on bioanalytical method stability implications of co-administered and co-formulated drugs by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4(17), 2117–2126 (2012).
  CASGoogle Scholar
• 26. Dechenne S, Yahvah K, Zimmer J. Validating stability and selectivity in the presence of co-administered compounds. Bioanalysis 11(20), 1819–1821 (2019).
  CASGoogle Scholar